Aytu BioPharma (NASDAQ:AYTU) Stock Price Passes Below 50-Day Moving Average – Should You Sell?

Aytu BioPharma Inc. (NASDAQ:AYTU)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.24 and traded as low as $1.99. Aytu BioPharma shares last traded at $1.99, with a volume of 61,012 shares traded.

Analysts Set New Price Targets

Several research analysts have recently commented on AYTU shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Ascendiant Capital Markets increased their target price on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aytu BioPharma presently has a consensus rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Stock Down 2.9%

The firm has a market cap of $21.35 million, a PE ratio of -0.43 and a beta of 0.26. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average price of $2.24 and a 200-day moving average price of $2.35.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new stake in shares of Aytu BioPharma in the 2nd quarter valued at approximately $2,336,646. Stonepine Capital Management LLC purchased a new position in Aytu BioPharma in the second quarter valued at $1,962,780. AWM Investment Company Inc. purchased a new position in Aytu BioPharma in the second quarter valued at $1,332,000. BlackRock Inc. acquired a new stake in Aytu BioPharma in the second quarter valued at $49,000. Finally, Crown Advisors Management Inc. acquired a new stake in Aytu BioPharma in the second quarter valued at $430,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.